Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer

被引:36
|
作者
Lee, Sandy C. [1 ]
Grant, Edward [1 ]
Sheth, Pulin [1 ]
Garcia, Agustin A. [3 ]
Desai, Bhushan [1 ]
Ji, Lingyun [2 ]
Groshen, Susan [2 ]
Hwang, Darryl [1 ]
Yamashita, Mary [1 ]
Hovanessian-Larsen, Linda [1 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Radiol, 1441 Eastlake Ave,Ground Floor,G360, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, 1441 Eastlake Ave,Ground Floor,G360, Los Angeles, CA 90033 USA
[3] Louisiana State Univ, Dept Internal Med, Sect Hematol Oncol, New Orleans, LA USA
关键词
breast cancer; breast ultrasound; contrast-enhanced ultrasound; neoadjuvant chemotherapy; magnetic resonance imaging; ultrasound; METAANALYSIS; SIZE;
D O I
10.7863/ultra.16.05060
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
ObjectivesThis pilot study compared contrast enhanced ultrasound (US) with contrast-enhanced magnetic resonance imaging (MRI) in assessing the treatment response in patients with breast cancer receiving preoperative neoadjuvant chemotherapy (NAC). MethodsThis prospective Institutional Review Board-approved and Health Insurance Portability and Accountability Act-compliant study included 30 patients, from January 2014 to October 2015, with invasive breast cancer detected by mammography, conventional US imaging, or both and scheduled for NAC. Informed consent was obtained. Contrast-enhanced US (perflutren lipid microspheres, 10 L/kg) and MRI (gadopentetate dimeglumine, 0.1 mmol/kg) scans were performed at baseline before starting NAC and after completing NAC before surgery. Results of the imaging techniques were compared with each other and with histopathologic findings obtained at surgery using the Spearman correlation. Tumor size and enhancement parameters were compared for 15 patients with contrast-enhanced US, MRI, and surgical pathologic findings. ResultsThe median tumor size at baseline was 3.1 cm on both contrast-enhanced US and MRI scans. The Spearman correlation showed strong agreement in tumor size at baseline between contrast-enhanced US and MRI (r=0.88; P<.001) but less agreement in tumor size after NAC (r=0.66; P=.004). Trends suggested that contrast-enhanced US (r=0.75; P<.001) had a better correlation than MRI (r=0.42; P=.095) with tumor size at surgery. Contrast-enhanced US was as effective as MRI in predicting a complete pathologic response (4 patients; 75.0% accuracy for both) and a non-complete pathologic response (11 patients; 72.7% accuracy for both). ConclusionsContrast enhanced US is a valuable imaging modality for assessing the treatment response in patients receiving NAC and had a comparable correlation as MRI with breast cancer size at surgery.
引用
收藏
页码:901 / 911
页数:11
相关论文
共 50 条
  • [41] Magnetic Resonance Imaging Evaluation of Pathological Response in Breast Cancer After Neoadjuvant Chemotherapy
    Akkavak Palazali, Gulcin
    Yilmaz, Ravza
    Palazali, Ozgkiour
    Dursun, Memduh
    INDIAN JOURNAL OF SURGERY, 2023, 85 (01) : 39 - 44
  • [42] Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype
    Fukuda, Takayo
    Horii, Rie
    Gomi, Naoya
    Miyagi, Yumi
    Takahashi, Shunji
    Ito, Yoshinori
    Akiyama, Futoshi
    Ohno, Shinji
    Iwase, Takuji
    SPRINGERPLUS, 2016, 5 : 1 - 9
  • [43] The value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the prediction of neoadjuvant chemotherapy response in breast cancer: A Meta-Analysis
    Dakhil, H. Abed
    Arian, A.
    Ahmadinejad, N.
    Bustan, R. A.
    Sahib, M. A.
    Anjomrooz, M.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2024, 22 (03):
  • [44] Prediction of treatment responses to neoadjuvant chemotherapy in breast cancer using contrast-enhanced ultrasound
    Huang, Yunxia
    Le, Jian
    Miao, Aiyu
    Zhi, Wenxiang
    Wang, Fen
    Chen, Yaling
    Zhou, Shichong
    Chang, Cai
    GLAND SURGERY, 2021, 10 (04) : 1280 - 1290
  • [45] Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer
    Kato, Erina
    Mori, Naoko
    Mugikura, Shunji
    Sato, Satoko
    Ishida, Takanori
    Takase, Kei
    JAPANESE JOURNAL OF RADIOLOGY, 2021, 39 (08) : 791 - 801
  • [46] Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer
    Erina Kato
    Naoko Mori
    Shunji Mugikura
    Satoko Sato
    Takanori Ishida
    Kei Takase
    Japanese Journal of Radiology, 2021, 39 : 791 - 801
  • [47] Dynamic Contrast Enhanced Magnetic Resonance Imaging vs 18 FDG PET CT in Assessing Response Following Neoadjuvant Chemotherapy in Patients with Breast Cancer
    Metta, J. R.
    Vani, C.
    Selvam, V.
    NH
    BREAST, 2025, 80
  • [48] Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate?
    David K. Woolf
    Anwar R. Padhani
    N. Jane Taylor
    Andrew Gogbashian
    Sonia P. Li
    Mark J. Beresford
    Mei-Lin Ah-See
    James Stirling
    David J. Collins
    Andreas Makris
    Breast Cancer Research and Treatment, 2014, 147 : 335 - 343
  • [49] Diagnostic accuracy of contrast-enhanced mammography vs MRI in evaluating the response of breast cancer treated with neoadjuvant chemotherapy
    Lopez, Angela Iglesias
    Alejandro, Alberto Bouzon
    Lopez, Laura Abelairas
    Oses, Joaquin Jose Mosquera
    Romero, Jose Ramon Varela
    Chaves, Andres Vega
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2023, 36 (01):
  • [50] Accuracy of magnetic resonance imaging prediction of pathologic complete response after neoadjuvant chemotherapy in breast cancer and its immunophenotypes
    Sabadell, M. D.
    Rodriguez-Arana, A.
    Garrigos, L.
    Vernet-Tomas, M.
    Alcantara, R.
    Servitja, S.
    Carreras, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S61 - S61